Cellmid Limited (ASX:CDY) is an Australian life sciences company with a consumer health business and biotech assets. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.
The Company also holds the most comprehensive intellectual property around midkine, an important growth factor implicated in various diseases including cancer, inflammatory diseases, bone healing and autoimmune conditions. Lyramid, Cellmid's wholly owned subsidiary has been commercializing these promising drug technologies.
For further information, please see www.cellmid.com.au and www.evolisproducts.com.au
